Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East

Jihyung Hong1, *, Diego Novick2, Maria Victoria Moneta3, Ahmed El-Shafei4, Héctor Dueñas5, Josep Maria Haro3
1 Department of Healthcare Management, Gachon University, Seongnam, South Korea
2 Eli Lilly and Company, Windlesham, Surrey, United Kingdom
3 Parc Sanitari Sant Joan de Déu, Fundació Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain;
4 Eli Lilly (Suisse) S.A., Dubai, United Arab Emirates
5 Eli Lilly de Mexico, Mexico City

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 625
Abstract HTML Views: 269
PDF Downloads: 192
ePub Downloads: 152
Total Views/Downloads: 1238
Unique Statistics:

Full-Text HTML Views: 434
Abstract HTML Views: 196
PDF Downloads: 160
ePub Downloads: 132
Total Views/Downloads: 922

Creative Commons License
© 2017 Hong et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Healthcare Management, College of Social Science, Gachon University, Seongnam-si, South Korea, 13120; Tel: +82 31 750 5205; E-mail:



The Global Burden of Disease 2010 study reported the relative size of major depressive disorder (MDD) burden to be greater in the Middle East and North Africa than anywhere else. However, little research has been carried out to examine the comparative effectiveness of antidepressants in this region.


To assess and compare functioning levels in Middle Eastern patients with MDD treated with either duloxetine or a selective serotonin reuptake inhibitor (SSRI), and to examine the impacts of depression-related pain on functioning by the type of treatment.


This post-hoc analysis, which focused on Middle Eastern patients, used data from a 6-month prospective observational study that included 1,549 MDD patients without sexual dysfunction. Levels of functional impairment and depression-related pain were assessed using the Sheehan Disability Scale (SDS) and the modified Somatic Symptom Inventory, respectively. A mixed model with repeated measures (MMRM) was employed.


The mean age of the patients was 37.3 (SD=8.4) years, and 34.6% were female. Patient functioning was, on average, moderately impaired at baseline, but improved substantially during follow-up in both the duloxetine (n=152) and the SSRI (n=123) cohorts. The MMRM results showed a lower level of functional impairment at 24 weeks in the duloxetine cohort than in the SSRI cohort (p<0.001). Pain severity at baseline was positively associated with functional impairment during follow-up only in the SSRI cohort (p=0.003).


Duloxetine-treated MDD patients achieved better functioning than SSRI-treated patients. This treatment difference was partly driven by depression-related pain.

Keywords: Depression , Antidepressant , Duloxetine , SSRI , Functioning , Middle East .